Improvements in patients with enthesitis at baseline
enthesitis
ENTHESITIS
Compared with placebo, improvements from baseline in LEI scores were greater with tofacitinib 10 mg BID at month 3 in patients with enthesitis at the lateral epicondyle humerus or medial femoral condyle, and greater with tofacitinib 5 mg BID in patients with 3–6 affected LEI sites at baseline (Fig. Change from baseline in LEI/SPARCC (patients with LEI > 0/SPARCC > 0 at baseline). *Indicates a comparison where the 95% CI for tofacitinib does not overlap with the 95% CI for placebo. 